AVP-786, with the CAS number 1079043-55-2, is a chemical compound that functions primarily as a novel therapeutic agent. It is a combination of a vasopressin V1A receptor antagonist and a deuterated form of the active metabolite of desmopressin, which is designed to enhance its pharmacological profile. AVP-786 has been investigated for its potential applications in treating various neuropsychiatric disorders, particularly in enhancing cognitive function and addressing symptoms associated with conditions like Alzheimer's disease. The compound exhibits a unique mechanism of action by modulating vasopressin receptors, which play a crucial role in memory and social behavior. Its pharmacokinetic properties are characterized by improved stability and bioavailability due to the incorporation of deuterium, which can lead to a prolonged half-life in the body. Overall, AVP-786 represents a promising avenue in drug development, particularly in the context of neurodegenerative diseases and cognitive enhancement. However, further clinical studies are necessary to fully understand its efficacy and safety profile.

AVP-786

1079043-55-2: AVP-786, with the CAS number 1079043-55-2, is a chemical compound that functions primarily as a novel therapeutic agent. It is a combination of a vasopressin V1A receptor antagonist and a deuterated form of the active metabolite of desmopressin, which is designed to enhance its pharmacological profile. AVP-786 has been investigated for its potential applications in treating various neuropsychiatric disorders, particularly in enhancing cognitive function and addressing symptoms associated with conditions like Alzheimer's disease. The compound exhibits a unique mechanism of action by modulating vasopressin receptors, which play a crucial role in memory and social behavior. Its pharmacokinetic properties are characterized by improved stability and bioavailability due to the incorporation of deuterium, which can lead to a prolonged half-life in the body. Overall, AVP-786 represents a promising avenue in drug development, particularly in the context of neurodegenerative diseases and cognitive enhancement. However, further clinical studies are necessary to fully understand its efficacy and safety profile.

CAS 1079043-55-2

AVP-786

Dextromethorphan-d6 HBr

Ref: 4Z-D-0321